452 results about "Helicobacter" patented technology

An oral pharmaceutical composition comprises an acid-labile irreversible proton pump inhibitor in pellet or tablet form, wherein the irreversible proton pump inhibitor is at least partly in slow-release form. On combined administration with an anti-microbially-active ingredient, the composition is distinguished by imparting an enhanced action of rapid onset against disorders caused by Helicobacter.

The present invention relates to methods of preventing or inhibiting the growth of Helicobacter through the use of a composition that comprises a glucosinolate, an isothiocyanate or a derivative or metabolite thereof. The present invention also relates to methods of preventing or treating persistent chronic gastritis, ulcers and / or stomach cancer in subjects at risk for, or in need of treatment thereof.

The present invention is based on the discovery of novel species of the genus Helicobacter that are associated with gastro-esophageal ulceration in pigs. In particular, a novel species, H. cerdo, has been used as a source of antigenic material for the development of vaccine for the treatment of the gastro-esophageal disorders. Most advantageously, the novel Helicobacter and the porcine circoviruses associated with PMWS in pigs are useful for providing combination vaccines whereby immunogens derived from both types of pathogens may be codelivered to the target animal to stimulate the generation of protective antibodies and immunity. The invention, therefore, provides vaccines that are useful for the tratment of gastro-esophageal ulceration and PMWS in porcines. The present invention includes, therefore, multivalent immunogenic compositions and vaccines, multivaccine kits, and combined immunization or vaccination methods which make it possible to use such combined immunization or vaccination programmes.

An oral pharmaceutical composition of pantoprazole in pellet or tablet form, wherein the pantoprazole is at least partly in slow-release form, is distinguished, on combined administration with an antimicrobially-active ingredient, by an enhanced action of rapid onset against disorders caused by Helicobacter.

The present invention discloses a new use of NO-releasing NSAIDs, especially NO-releasing NSAIDs of the formula I, or a pharmaceutically acceptable salt or enantiomer thereof, for the manufacture of a medicament for the treatment of bacterial infections, especially caused or mediated by Helicobacter pylon.Disclosed is also the new use of a NO-releasing NSAID in combination with an acid susceptible proton pump inhibitor for the treatment of bacterial infections.

The invention provides a therapeutical composition comprising purified fractions of compounds being or containing a pathogen-inhibiting oligosaccharide sequence for use as a medicament. The present invention especially describes an oligosaccharide-containing substance or receptor binding to diarrheagenic Escherichia coli and / or zoonotic Helicobacter species, and use thereof in, e.g., pharmaceutical, nutritional and other compositions for prophylaxis and treatment of conditions due to the presence of Escherichia coli and / or zoonotic Helicobacter species. The invention is also directed to the use of the receptors for diagnostics of Escherichia coli and / or zoonotic Helicobacter species.

The present invention is an apparatus for detecting the presence of exhaled ammonia and a method for using the same to detect the present of a Helicobacter in a subject. The apparatus is composed of a breath capture device having a sensor plate with at least one selected Lewis acid dye (e.g., a metal ion-containing dye such as a metalloporphyrin) deposited thereon which produces a detectable spectral, transmission or reflectance response in the presence of ammonia.

Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and / or vaccination against disease are provided. Delivery of the pharamacologically active molecules is provided at the mucosal surface, such as the gastric mucosa or nasal membranes, to provide effective and continuous delivery of a pharmacologically active agent. In some embodiments, the Helicobacter provides exposure of a desired molecule of interest though the surface of the Helicobacter, providing exposure of the antigen to the host at the gastric mucosa. Live Helicobacter pylori vaccines are also provided. Vectors and shuttle vector constructs of the Helicobacter are also disclosed.

The present invention provides ketolide derivatives, which can be used as antibacterial agents. In particular, compounds described herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp. Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebaclerium, Bacillus or Enterobactericeae. Also provided are processes for preparing such ketolide derivatives, pharmaceutical compositions thereof, and methods of treating bacterial infections.

The invention relates to the field of the emulsion method immune chromatography, and particularly relates to a detection kit of a helicobacter pylori emulsion method. The detection kit of the helicobacter pylori emulsion method comprises a reagent strip, wherein the reagent strip comprises a substrate, filter sample paper, a sensitized emulsion polyester film, an immune cellulose nitrate film and absorbent paper, wherein the filter sample paper, the sensitized emulsion polyester film, the immune cellulose nitrate film, and the absorbent paper are orderly connected end to end, and are fixed on the substrate, the immune cellulose nitrate film is covered with helicobacter pylori resisting urea enzyme antibodies I marked by colorful emulsion particles, and the immune cellulose nitrate film is provided with a detection line coated with helicobacter pylori resisting urea enzyme antibodies II and a quality control line coated by goat anti-rabbit serum IgG. The detection kit of the helicobacter pylori emulsion method, which is provided by the invention, has the advantages of convenience in detection, stability in detection results and cost conservation.

The invention discloses application of a Harmine derivative to preparation of antibacterial medicines. The bacteria is selected from Acinetobacter, Bacillus, Campylobacter, Chlamydia, Chlamydia trachomatis, Clostridium, Citrobacter, Escherichia, enterohemorrhagic escherichia coli, enteric bacteria, Enterococcus, Francisella, Haemophilus, helicobacter, Klebsiella Bacillus, Lester monocytogenes, Moraxella, Mycobacterium, Neisseria, proteus, Pseudomonas, Salmonella, shewanella oneidensis, Shigella, Stenotrophomonas, Staphylococcus, Streptococcus and Yersinia.

The invention discloses a Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano vaccine. According to the Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano vaccine, a virus receptor binding domain (RBD) is used as an antigen and is connected with a helicobacter pylori polymer protein (HP _ Ferritin) to form a fusion protein RBD-HP_ Ferritin, so that antigen multimerization is realized; and expressing by using an eukaryotic cell expression system is carried out, so as to form a 24-polymer nano antigen through the self-assembly action of HP _ Ferritin. According to the scheme, the defect that RBD monomers are insufficient in immunogenicity can be overcome, the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses, and the generated antibodies have the capacity of strongly preventing the viruses from invading target cells. Moreover, the vaccine is simple in preparation method, easy to purify and high in safety, and can be quickly applied to clinical tests.

The invention relates to an oral hard capsule, in particular to an oral hard capsule filled with different medicament active ingredient tablets and used for treating infection caused by helicobacter pylori. The technical scheme is realized in such a way that tablets containing antibiotics and wrapping enteric coating, soluble salt tablets of bismuth and / or gastric acid depressant tablets are filled into a capsule, thereby providing an administration dosage form which has simpler preparation process and can enable all the medicaments to be beautifully taken by a trilogy / quadruple chemotherapy. The active ingredients with the dosage form do not contact mutually, thus different active ingredients can be separately measured in medicament detection.

Compositions and methods for treating, preventing and diagnosing Helicobacter infection are disclosed. The methods use proteins and / or nucleic acids derived from Helicobacter cerdo, a new pathogen isolated from swine.

Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and / or vaccination against disease are provided. Delivery of the pharamacologically active molecules is provided at the mucosal surface, such as the gastric mucosa or nasal membranes, to provide effective and continuous delivery of a pharmacologically active agent. Vectors and shuttle vector constructs are also provided

The invention discloses a compound probiotic functional food capable of inhibiting helicobacter pylori. The compound probiotic functional food capable of inhibiting helicobacter pylori comprises 20-40parts of prebiotics, 20-30 parts of bacillus bifidus flora, 10-20 parts of bacillus acidophilus, 5-10 parts of lactobacillus casei, 5-10 parts of lactobacillus reuteri, 3-8 parts of lactobacillus paracasei, 3-8 parts of lactobacillus gasseri and 5-10 parts of lactobacillus rhamnosus. A preparation method of the compound probiotic functional food capable of inhibiting helicobacter pylori comprisesthe following steps: performing pretreatment on raw materials, namely putting weighed raw materials into a dry mixer so as to be subjected to uniform mixing; putting the mixed materials into a tabletmachine and performing tablet compression so as to obtain tablets, or directly weighing and bagging the mixed materials; and then, carrying out laboratory testing, and warehousing qualified productsso as to obtain finished products. The compound probiotic functional food capable of inhibiting helicobacter pylori solves the problem of existing functional foods, namely insufficient inhibition on helicobacter pylori production and spread of helicobacter pylori due to lack of variety of bacterial flora and unscientific proportion.

The invention provides a recombination antigen composition, a vaccine and a carrier and a method for preparing the antigen composition. A recombination helicobacter pylori antigen which comprises a helicobacter pylori antigen, the fusion proteins of a cholera toxin CT-A2 subunit and cholera toxin CT-B proteins is optimized. The compatibility of the CT-A2 and the CT-B proteins is used, a chimeric structure of CT-A2-5CT-B is formed, and accordingly an antigen with higher titer is formed through the helicobacter pylori antigen and the fusion proteins of the cholera toxin CT-A2 subunit. Meanwhile, the effect that the CT-B enhances immunization is used, and the effect that the antigen immunogenicity of the recombination antigen composition is enhanced is achieved. In addition, the chimeric protein constituted by the recombination antigen stimulates a mucous membrane to generate secreting type IgA immunization.

The invention relates to the technical field of food enzymes, and discloses a symbiotic microflora enzyme. The symbiotic microflora enzyme contains symbiotic microflora which has the effect of preventing, resisting and inhibiting helicobacter pylori. The symbiotic microflora contains main microflora and auxiliary microflora which aim at enhancing microflora effects and increasing the microflora number, wherein the main microflora comprises lactobacillus acidophilus, lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus rhamnosus, Roy's lactobacillus, lactobacillus casei, lactobacillus gasseri, lactobacillus johnsonii, lactobacillus salivarius, lactobacillus brevis, lactic streptococci, bacillus subtilis, bifidobacterium bifidum, bifidobacterium adolescentis, bifidobacterium infantis, bifidobacterium breve and bifidobacterium longum. After the symbiotic microflora enzyme is drunk, the contained powerful and rich symbiotic microflora can naturally exist in the digestive system of the human body, obtains the living space advantage in the ecological environment, and achieves the effect of eliminating helicobacter pylori.

The invention discloses a helicobacter pylori ferritin-based novel coronavirus S protein double-region subunit nanovaccine. According to the invention, a receptor binding domain (RBD) of a virus and afusion peptide (FP) are jointly used as double antigens, and the double antigens are connected with a helicobacter pylori polymer protein (HP _ Ferritin) to form a fusion protein RBD-FP-HP _ Ferritin, so that antigen multimerization is realized; and then an eukaryotic cell expression system is utilized for expression, so as to form a 24-polymer nano antigen through the self-assembly action of HP_ Ferritin. According to the scheme, the defect that RBD monomers are insufficient in immunogenicity can be overcome, the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses, and the generated antibodies have the capacity of strongly preventing the viruses from invading target cells. Moreover, the vaccine is simple in preparation method, easy to purifyand high in safety, and can be quickly applied to clinical tests.

The present invention provides a Bifidobacterium lactis capable of regulating gastrointestinal florae and application of the Bifidobacterium lactis BL-99, and belongs to the technical field of microorganisms. The Bifidobacterium lactis has gastric acid resistance, the survival rate of viable bacteria is 62% or above after the Bifidobacterium lactis BL-99 is treated for 30 min in a pH 2.5 gastric acid solution, and the survival rate of viable bacteria is 61% or above after the Bifidobacterium lactis BL-99 is treated for 2 h. The bacterium can significantly promote the growth of bifidobacteria and lactic acid bacteria, and can inhibit desulphovibrio / enterobacter in intestinal tracts, especially curatively inhibit helicobacter pylori and / or Escherichia-Shigella, can be used to prepare food, medicines and feed with gastrointestinal tract flora regulation effects, and has wide application prospects.

The present invention provides ketolide derivatives, which can be used as anti-bacterial agents. Compounds disclosed herein can be used for the treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus, Enterobactericeae or any combination thereof. Also provided are processes for preparing compounds disclosed herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods of treating bacterial infections.

The invention provides a method of screening a bacterial strain capable of inhibiting helicobacter pylori. The method includes a way that qualitative and quantitative assessment can be directly conducted on screened bacterial strains if the screened bacterial strains can inhibit or eliminate the colonization of the helicobacter pylori on gastric mucosal cells by utilizing DNA fluorescent labels and flow cytometry. According to the invention, the following points are considered when conducting screening model tests in vitro: (1) viability in an extremely acidic stomach environment; (2) inhibition ability of the bacterial strains itself or metabolites of the bacterial strains to HP reproduction in vitro; and (3) ability of inhibiting or relieving the colonization of the helicobacter pylori strains on gastric mucosa. According to the invention, developing the method of directly assessing in vitro if the HP colonization can be inhibited is of great significance to the practical applicationof the bacterial strain provided by the invention. According to the invention, lactobacillus acidophilus LA-10A capable of inhibiting the helicobacter pylori is screened out. According to a test, thelactobacillus acidophilus LA-10A can relieve or prevent the helicobacter pylori infection. The lactobacillus acidophilus LA-10A can be used to prepare functional food or pharmaceutical compositions.

The invention relates to a multiplex PCR-based synchronous and rapid method for detecting 13 pathogenic microorganisms in water, which comprises the steps of using multiplex PCR to simultaneously amplify gene-specific fragments of the 13 pathogenic microorganisms including escherichia coli, enterohaemorragic escherichia coli o157:h7, legionella pneumophila, salmonella enteritidis, shigella dysenteriae, staphyloccocus aureus, listeria monoeytogenes, helicobacter pylori, mycobacterium tuberculosis, klebsiella pneumonia, vibrio cholera, bacillus anthracis and yersinia pestis, and detecting PCR amplified products through agarose gel electrophoresis, thereby achieving synchronous and rapid detection for the 13 pathogenic microorganisms.

The present invention relates to methods for treating pathological conditions associated with Helicobacter sp infections, specifically H. pylori infection. The present invention further relates to methods for treating pathologies characterized by excess gastric acid secretion. The methods of the present invention comprise oral administration of pentagastrin effective locally in the stomach in conjunction with a gastric proton pump inhibitor. It is disclosed herein for the first time that PG administered orally exerts a local effect in the stomach and may be used in combination with a PPI for treating pathological conditions characterized by excess gastric acid secretion and in pathological conditions associated with Helicobacter sp infections.

The present invention provides a new application of lactobacillus paracausei K56 capable of adjusting gastrointestinal flora balance. The lactobacillus paracasei (lactobacillus paracausei subsp.paracasei) has a preservation number of DSM27447. The strain of the single bacteria has ability to significantly promote growth of intestinal bifidobacteria and lactic acid bacteria, can inhibit desulphovibrio and / or enterobacter, can inhibit helicobacter pylori and / or escherichia-shigella genera, and can tolerate stress environment of simulated gastrointestinal fluid in vitro. Mouse experiments show that the strain has no oral acute toxicity and no antibiotic resistance, is safe and can be used for food processing.

A method for the in vivo detection of urease-producing helicobacter in the upper stomach is disclosed. The dense carrier is divided into two separate groups which are combined with separate reagent indicators, one of which also contains urea. The carriers are food soluble products, preferably sugar beads having a diameter of approximately 0.2 to 3.0 mm. The treated carriers and urea are encapsulated in a soluble capsule which is administered to a patient. The density of the carriers cause the capsule to migrate to the gastric mucosa, where the capsule, but not the reagents, is dissolved, placing the reagents and urea in direct contact with the gastric mucosa. The urea reacts with any urease present in the stomach by creating ammonia, which increases the pH in the immediate vicinity of the urea containing carrier and indicator beads. The two reagents react differently, through color change, to the increase in pH, which is viewed through use of an endoscope. A preferred first reagent is bromothymol blue (dibromothymolsulfonphthalein), which changes yellow in the presence of urease, and a preferred second reagent is phenol red (phenolsulfonphthalein), which turns red in the presence of urease.

The present invention relates to one kind of immuno-colloidal gold test paper for detecting pyloric helicobacter antigen and its preparation process. The test paper has coated urease monoclonal antibody, CagA or VacA monoclonal antibody and anti-mouse polyclonal antibody. It is used in detecting pyloric helicobacter related antigen existing in saliva, gastric juice, vomited matter, dental plaque and excrement of mammal so as to monitor the infection status of pyloric helicobacter, assist the diagnosis of gastritis, peptic ulcer and other diseases and predict gastric cancer probability. The present invention simple operation, high specificity and high sensitivity.

The invention provides sugarcane compound microbial fertilizer which comprises the following compositions by weight percent: 7-9 wt% of active functional bacteria, 1-3 wt% of a soil improvement agent, 40-50 wt% of organic fertilizer, 40-50 wt% of inorganic compound fertilizer, wherein the total percent of all the compositions is 100%. The invention further discloses a preparation method for the sugarcane compound microbial fertilizer. According to the invention, the micro-ecological environment of rhizosphere soil of plants can be activated through the mutual effect of bacteria for nitrogen fixation, phosphorus solubilization and potassium solubilization such as nitrogen fixation helicobacter, bacillus megaterium, and bacillus mucilaginosus and the 'E-2001' soil improvement agent; nitrogen fixation can be realized, and nutrient elements such as potassium, phosphorus, and magnesium which are difficult to dissolve can be converted into soluble nutrients, so that available nutrient content in soil is increased, chemical fertilizer consumption is reduced, and the utilization rate of the fertilizer is improved by 32%; the crop growth and development are facilitated, the stress resistance is enhanced, the sugarcane yield is increased by 25%, and the sugar degree is increased by 1-2 degrees.

Provided herein are ketolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus, Enterobactericeae, Propionibacterium acnes or any combination thereof. Also provided are processes for preparation of compounds described herein, pharmaceutical compositions thereof, and methods of treating bacterial infections.

Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.